Vanguard Group Inc Monopar Therapeutics Put Options Transaction History
Vanguard Group Inc
- $5.12 Trillion
- Q2 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding MNPR
# of Institutions
10Shares Held
379KCall Options Held
0Put Options Held
0-
Israel Englander Millennium Management LLC | New York, Ny194KShares$3 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA60KShares$926,3550.0% of portfolio
-
Two Sigma Securities, LLC New York, NY47.1KShares$726,1040.0% of portfolio
-
Virtu Financial LLC New York, NY18.8KShares$290,7010.0% of portfolio
-
Tower Research Capital LLC (Trc) New York, NY7.92KShares$122,2360.0% of portfolio
About Monopar Therapeutics
- Ticker MNPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 12,725,800
- Market Cap $196M
- Description
- Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe ...